An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity

References

• Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, Baba Y, Kumar A. (2004). Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 42:341–353.
   PubMedGoogle Scholar
• Ahn JH, Kang YK, Kim TW, Bahng H, Chang HM, Kang WC, Kim WK, Lee JS, Park JS. (2002). Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemother Pharmacol 50:104–110.
   PubMedGoogle Scholar
• Ali BH, Al-Moundhri M, Tageldin M, Al Husseini IS, Mansour MA, Nemmar A, Tanira MO. (2008). Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol 46:3355–3359.
   PubMed Web of Science ®Google Scholar
• Antunes LM, Darin JD, Bianchi Nde L. (2001). Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43:145–150.
   PubMed Web of Science ®Google Scholar
• Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P. (2003). Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. Cancer Invest 21:489–496.
   PubMed Web of Science ®Google Scholar
• Arany I, Safirstein RL. (2003). Cisplatin nephrotoxicity. Semin Nephrol 23:460–464.
   PubMed Web of Science ®Google Scholar
• Arany I, Megyesi JK, Kaneto H, Price PM, Safirstein RL. (2004). Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287:F543–F549.
   PubMed Web of Science ®Google Scholar
• Argiris A, Li Y, Murphy BA, Langer CJ, Forastiere AA. (2004). Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22:262–268.
   PubMed Web of Science ®Google Scholar
• Aydinoz S, Uzun G, Cermik H, Atasoyu EM, Yildiz S, Karagoz B, Evrenkaya R. (2007). Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity. Ren Fail 29:257–263.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM. (2007). A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2:638–644.
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C; Italian Sarcoma Group/Scandinavian Sarcoma Group. (2002). High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 14:198–206.
   PubMed Web of Science ®Google Scholar
• Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH. (2005). Naringenin attenuates cisplatin nephrotoxicity in rats. Life Sci 76:2125–2135.
   PubMed Web of Science ®Google Scholar
• Bae EH, Lee J, Ma SK, Kim IJ, Frøkiaer J, Nielsen S, Kim SY, Kim SW. (2009). alpha-Lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrol Dial Transplant 24:2692–2700.
   PubMed Web of Science ®Google Scholar
• Barabas K, Milner R, Lurie D, Adin C. (2008). Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 6:1–18.
   PubMed Web of Science ®Google Scholar
• Bearcroft CP, Domizio P, Mourad FH, André EA, Farthing MJ. (1999). Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine. Gut 44:174–179.
   PubMedGoogle Scholar
• Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. (2008). Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer 99:57–62.
   PubMedGoogle Scholar
• Boulikas T. (2009. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18:1197–1218.
   PubMed Web of Science ®Google Scholar
• Boyce M, Yuan J. (2006). Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 13:363–373.
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, Goligorsky MS. (2002). Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 282:F1140–F1149.
   PubMed Web of Science ®Google Scholar
• Brooks C, Wei Q, Cho SG, Dong Z. (2009). Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 119:1275–1285.
   PubMed Web of Science ®Google Scholar
• Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA. (2010). Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159:898–908.
   PubMed Web of Science ®Google Scholar
• Cetin R, Devrim E, Kiliçoglu B, Avci A, Candir O, Durak I. (2006). Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J Appl Toxicol 26:42–46.
   PubMed Web of Science ®Google Scholar
• Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M. (2002). L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 405:55–64.
   PubMed Web of Science ®Google Scholar
• Chiara S, Lionetto R, Vincenti M, Bruzzone M, Nobile MT, Gadducci A, Carnino F, Rosso R, Conte PF. (2001. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit Rev Oncol Hematol 37:27–34.
   PubMedGoogle Scholar
• Chirino YI, Pedraza-Chaverri J. (2009). Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 61:223–242.
   PubMed Web of Science ®Google Scholar
• Chirino YI, Trujillo J, Sánchez-González DJ, Martínez-Martínez CM, Cruz C, Bobadilla NA, Pedraza-Chaverri J. (2008). Selective iNOS inhibition reduces renal damage induced by cisplatin. Toxicol Lett 176:48–57.
   PubMed Web of Science ®Google Scholar
• Choi DE, Jeong JY, Lim BJ, Lee KW, Shin YT, Na KR. (2009). Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity. Korean J Intern Med 24:238–246.
   PubMedGoogle Scholar
• Choudhury D, Ahmed Z. (2006). Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2:80–91.
   PubMedGoogle Scholar
• Chumworathayi B, Yuenyao P, Tangvorapongchai V, Luanratanakorn S, Pattamadilok J, Krusun S. (2007). Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women. Radiat Med 25:474–479.
   PubMedGoogle Scholar
• Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, Pavenstädt H, Lanvers-Kaminsky C, am Zehnhoff-Dinnesen A, Schinkel AH, Koepsell H, Jürgens H, Schlatter E. (2010). Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176:1169–1180.
   PubMed Web of Science ®Google Scholar
• Cohen SM, Lippard SJ. (2001). Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93–130.
   PubMed Web of Science ®Google Scholar
• Cornelison TL, Reed E. (1993). Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol 50:147–158.
   PubMed Web of Science ®Google Scholar
• Cubillo A, Cornide M, López JL, Molina R, Feliu J, Espinosa E, Zamora P, de Castro J, Ordoñez A, González Barón M. 2001. Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol 24:192–197.
   PubMedGoogle Scholar
• Cummings BS, McHowat J, Schnellmann RG. (2004). Role of an endoplasmic reticulum Ca2+-independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J Pharmacol Exp Ther 308:921–928.
   PubMedGoogle Scholar
• Cummings BS, Schnellmann RG. (2002). Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 302:8–17.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Abildgaard U. (1989). Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol 25:1–9.
   PubMed Web of Science ®Google Scholar
• de Jongh R, Groenink L, van der Gugten J, Olivier B. (2003). Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone. Biol Psychiatry 54:1041–1048.
   PubMed Web of Science ®Google Scholar
• Delbancut A, Lagroye I, Cambar J. (1994). Renal cytotoxicity of cisplatin in cultured glomerular mesangial and proximal and distal tubular cells. Toxicol In Vitro 8:517–519.
   PubMedGoogle Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26:3279–3290.
   PubMed Web of Science ®Google Scholar
• Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H, Marini L. (2007). Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 52:134–141.
   PubMed Web of Science ®Google Scholar
• Dong G, Luo J, Kumar V, Dong Z. (2010). Inhibitors of histone deacetylases suppress cisplatin-induced p53 activation and apoptosis in renal tubular cells. Am J Physiol Renal Physiol 298:F293–F300.
   Google Scholar
• dos Santos OF, Boim MA, Barros EJ, Pirotzky E, Braquet P, Schor N. (1991). Effect of platelet-activating factor antagonist BN 52063 on the nephrotoxicity of cisplatin. Lipids 26:1324–1328.
   PubMedGoogle Scholar
• Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. (2006). Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25:6800–6816.
   PubMed Web of Science ®Google Scholar
• Eardley KS, Kubal C, Zehnder D, Quinkler M, Lepenies J, Savage CO, Howie AJ, Kaur K, Cooper MS, Adu D, Cockwell P. (2008). The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 74:495–504.
   PubMed Web of Science ®Google Scholar
• Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S, Ehrsson H. (2003). Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 51:36–42.
   PubMed Web of Science ®Google Scholar
• Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. (1999). 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 86:861–865.
   PubMed Web of Science ®Google Scholar
• Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. (2007). Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322:8–15.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G; Italian and Scandinavian Sarcoma Groups. (2005). Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845–8852.
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. (2009). Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396–402.
   PubMed Web of Science ®Google Scholar
• Francescato HD, Costa RS, Júnior FB, Coimbra TM. (2007). Effect of JNK inhibition on cisplatin-induced renal damage. Nephrol Dial Transplant 22:2138–2148.
   PubMed Web of Science ®Google Scholar
• Francescato HD, Costa RS, da Silva CG, Coimbra TM. (2009). Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Life Sci 84:590–597.
   Google Scholar
• Fujieda, M., Matsunaga, A., Hayashi, A., Tauchi, H., Chayama, K., and Sekine, T. (2009). Children’s toxicology from bench to bed–Drug-induced renal injury (2): Nephrotoxicity induced by cisplatin and ifosfamide in children. J Toxicol Sci 34 Suppl 2 SP251–257.
   Google Scholar
• Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, De Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G. (2000). Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390–3399.
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D. (2005). Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945.
   PubMed Web of Science ®Google Scholar
• Gill A, Wortham K, Costa D, Davis W, Ticho B, Whalley E. (2009). Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats. Am J Nephrol 30:521–526.
   PubMedGoogle Scholar
• Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. (1977). The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39:1362–1371.
   PubMed Web of Science ®Google Scholar
• Goren MP. 2003. Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Med Pediatr Oncol 41:186–189.
   PubMedGoogle Scholar
• Grande MT, López-Novoa JM. (2009). Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol 5:319–328.
   PubMed Web of Science ®Google Scholar
• Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. (2001). Adult medulloblastoma: multiagent chemotherapy. Neuro-oncology 3:29–34.
   PubMed Web of Science ®Google Scholar
• Groth S, Nielsen H, Sørensen JB, Christensen AB, Pedersen AG, Rørth M. (1986). Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol 17:191–196.
   PubMedGoogle Scholar
• Guinee DG Jr, van Zee B, Houghton DC. (1993). Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer 71:4050–4054.
   PubMedGoogle Scholar
• Guo Y, Liu Y, Xu LG, Guo MY. (2006). Protective effect of amifostine on cisplatin-induced nephrotoxicity and its mechanism. Zhonghua Zhong Liu Za Zhi 28:8–12.
   PubMedGoogle Scholar
• Hamilton RW, Hopkins MB 3rd, Shihabi ZK. (1989). Myoglobinuria, hemoglobinuria, and acute renal failure. Clin Chem 35:1713–1720.
   PubMedGoogle Scholar
• Hye Khan MA, Abdul Sattar M, Abdullah NA, Johns EJ. (2007). Cisplatin-induced nephrotoxicity causes altered renal hemodynamics in Wistar Kyoto and spontaneously hypertensive rats: role of augmented renal alpha-adrenergic responsiveness. Exp Toxicol Pathol 59:253–260.
   PubMedGoogle Scholar
• Iseri S, Ercan F, Gedik N, Yüksel M, Alican I. (2007). Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology 230:256–264.
   PubMed Web of Science ®Google Scholar
• Isnard-Bagnis C, Moulin B, Launay-Vacher V, Izzedine H, Tostivint I, Deray G. (2005). Anticancer drug-induced nephrotoxicity. Nephrol Ther 1:101–114.
   PubMedGoogle Scholar
• Jiang M, Wei Q, Pabla N, Dong G, Wang CY, Yang T, Smith SB, Dong Z. (2007). Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity. Biochem Pharmacol 73:1499–1510.
   PubMed Web of Science ®Google Scholar
• Jiang M, Wang CY, Huang S, Yang T, Dong Z. (2009). Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol 296:F983–F993.
   Google Scholar
• Jo SK, Cho WY, Sung SA, Kim HK, Won NH. (2005). MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 67:458–466.
   PubMed Web of Science ®Google Scholar
• Jones R, Ryan M, Friedlander M. (2003). Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 89:112–115.
   PubMed Web of Science ®Google Scholar
• Jones DP, Spunt SL, Green D, Springate JE; Children’s Oncology Group. (2008). Renal late effects in patients treated for cancer in childhood: a report from the Children’s Oncology Group. Pediatr Blood Cancer 51:724–731.
   PubMed Web of Science ®Google Scholar
• Kang DG, Lee AS, Mun YJ, Woo WH, Kim YC, Sohn EJ, Moon MK, Lee HS. (2004). Butein ameliorates renal concentrating ability in cisplatin-induced acute renal failure in rats. Biol Pharm Bull 27:366–370.
   PubMed Web of Science ®Google Scholar
• Kang KP, Kim DH, Jung YJ, Lee AS, Lee S, Lee SY, Jang KY, Sung MJ, Park SK, Kim W. (2009). Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant 24:3012–3020.
   PubMed Web of Science ®Google Scholar
• Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, Kaissling B, Bachmann S, Koepsell H. (2000). Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol 279:F679–F687.
   PubMed Web of Science ®Google Scholar
• Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C. (2010). Drugs renal toxicity. Nephrol Ther 6:58–74.
   PubMedGoogle Scholar
• Kaushal GP, Kaushal V, Hong X, Shah SV. (2001). Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 60:1726–1736.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. (2005). Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 28:1385–1388.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. (2006). Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J Pharmacol Sci 100:65–72.
   PubMed Web of Science ®Google Scholar
• Kawai Y, Satoh T, Hibi D, Ohno Y, Kohda Y, Miura K, Gemba M. (2009). The effect of antioxidant on development of fibrosis by cisplatin in rats. J Pharmacol Sci 111:433–439.
   PubMedGoogle Scholar
• Khan AH, Sattar MA, Abdullah NA, Johns EJ. (2007). Influence of cisplatin-induced renal failure on the alpha(1)-adrenoceptor subtype causing vasoconstriction in the kidney of the rat. Eur J Pharmacol 569:110–118.
   PubMed Web of Science ®Google Scholar
• Khan MA, Sattar MA, Abdullah NA, Johns EJ. (2008). Alpha1B-adrenoceptors mediate adrenergically-induced renal vasoconstrictions in rats with renal impairment. Acta Pharmacol Sin 29:193–203.
   PubMedGoogle Scholar
• Khan AH, Sattar MA, Abdullah NA, Johns EJ. (2009). Effect of calcium channel blockade on adrenergically induced renal vasoconstriction in rat models of renal impairment. Clin Exp Pharmacol Physiol 36:501–508.
   PubMedGoogle Scholar
• Kim YK, Kim HJ, Kwon CH, Kim JH, Woo JS, Jung JS, Kim JM. (2005). Role of ERK activation in cisplatin-induced apoptosis in OK renal epithelial cells. J Appl Toxicol 25:374–382.
   PubMed Web of Science ®Google Scholar
• Kintzel PE. (2001). Anticancer drug-induced kidney disorders. Drug Saf 24:19–38.
   PubMed Web of Science ®Google Scholar
• Kishore BK, Krane CM, Di Iulio D, Menon AG, Cacini W. (2000). Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria. Kidney Int 58:701–711.
   PubMed Web of Science ®Google Scholar
• Klaasen CD. (2001). Casarett & Doull’s Toxicology: The Basic Science of Poisons, 6th edn. New York., Mc Graw-Hill
   Google Scholar
• Kohn S, Fradis M, Ben-David J, Zidan J, Robinson E. (2002). Nephrotoxicity of combined treatment with cisplatin and gentamicin in the guinea pig: glomerular injury findings. Ultrastruct Pathol 26:371–382.
   PubMed Web of Science ®Google Scholar
• Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW. (2001). Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 6:488–495.
   PubMed Web of Science ®Google Scholar
• Kröning R, Lichtenstein AK, Nagami GT. (2000). Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol 45:43–49.
   PubMed Web of Science ®Google Scholar
• Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. (2007). Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 55:10150–10155.
   PubMed Web of Science ®Google Scholar
• Kuhlmann MK, Burkhardt G, Köhler H. (1997). Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant 12:2478–2480.
   PubMed Web of Science ®Google Scholar
• Kuhnt T, Becker A, Pigorsch S, Pelz T, Bloching M, Passmann M, Lotterer E, Hänsgen G, Dunst J. (2003. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 179:673–681.
   PubMedGoogle Scholar
• Kuo YM, Gybina AA, Pyatskowit JW, Gitschier J, Prohaska JR. (2006). Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J Nutr 136:21–26.
   PubMed Web of Science ®Google Scholar
• Kuriakose GC, Kurup MG. (2008. Evaluation of renoprotective effect of Aphanizomenon flos-aquae on cisplatin-induced renal dysfunction in rats. Ren Fail 30:717–725.
   PubMed Web of Science ®Google Scholar
• Lajer H, Kristensen M, Hansen HH, Christensen S, Jonassen T, Daugaard G. (2005). Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemother Pharmacol 55:231–236.
   PubMedGoogle Scholar
• Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B, Vallette FM. (2007). Bax activation and mitochondrial insertion during apoptosis. Apoptosis 12:887–896.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Ayllon J, Janus N, Spano JP, Ray-Coquard I, Gligorov J, Pourrat X, Morere JF, Beuzeboc P, Deray G, Oudard S; Renal insufficiency and anticancer medications (irma) study group. (2009). Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer 7:E83–E89.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M; European Society of Clinical Pharmacy Special Interest Group on Cancer Care. (2008a). Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903–909.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G. (2008b). Chemotherapy and renal toxicity. Bull Cancer 95 FMC Onco:F96–103.
   Google Scholar
• Lebwohl D, Canetta R. (1998). Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522–1534.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang YB, Lee JE, Jang KY, Park SK. (2006. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 21:2096–2105.
   PubMed Web of Science ®Google Scholar
• Li CJ, Sun JL, Jiang WJ, Liu LS, Sun XY, Fan GZ. (2009). Effect of cisplatin on expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and their correlations in Lewis lung cancer in mice. Ai Zheng 28:685–690.
   PubMedGoogle Scholar
• Liedert B, Pluim D, Schellens J, Thomale J. (2006). Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei. Nucleic Acids Res 34:e47.
   PubMed Web of Science ®Google Scholar
• Lin A, Jabbari S, Worden FP, Bradford CR, Chepeha DB, Teknos TN, Liao JJ, Nyquist GG, Tsien C, Schipper MJ, Urba S, Wolf GT, Eisbruch A. (2005). Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys 63:1413–1418.
   PubMed Web of Science ®Google Scholar
• Liu H, Baliga R. (2003. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 63:1687–1696.
   PubMed Web of Science ®Google Scholar
• Lu LH, Oh DJ, Dursun B, He Z, Hoke TS, Faubel S, Edelstein CL. (2008). Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J Pharmacol Exp Ther 324:111–117.
   PubMedGoogle Scholar
• Luke DR, Vadiei K, Lopez-Berestein G. (1992). Role of vascular congestion in cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 7:1–7.
   PubMed Web of Science ®Google Scholar
• Martinez G, Costantino G, Clementi A, Puglia M, Clementi S, Cantarella G, De Meo L, Matera M. (2009). Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3. Exp Toxicol Pathol 61:183–188.
   PubMed Web of Science ®Google Scholar
• Martínez-Salgado C, García-Cenador B, Fuentes-Calvo I, Macías Núñez JF, López-Novoa JM. (2007). Effect of adenosine in extracellular matrix synthesis in human and rat mesangial cells. Mol Cell Biochem 305:163–169.
   PubMedGoogle Scholar
• Mené P, Simonson MS, Dunn MJ. (1989). Physiology of the mesangial cell. Physiol Rev 69:1347–1424.
   PubMed Web of Science ®Google Scholar
• Meyer KB, Madias NE. (1994). Cisplatin nephrotoxicity. Miner Electrolyte Metab 20:201–213.
   PubMedGoogle Scholar
• Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, Koepsell H. (1998). Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun 248:673–678.
   PubMed Web of Science ®Google Scholar
• Mihaylova Zh, Ludovini V, Gregorg V, Floriani I, Pistola L, Toffaneti F, Ferraldeschi M, Spreafico A, Ceresoli GL, Bellet M, Darwish S, Tonato M, Raynov J. (2007). Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. J Buon 12:105–111.
   PubMedGoogle Scholar
• Moscetti L, Nelli F, Padalino D, Sperduti I, Giannarelli D, Pollera CF. (2005). Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. J Chemother 17:685–692.
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, Inui K. (2002). Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866–874.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. (2000). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18:106–115.
   PubMed Web of Science ®Google Scholar
• Mukai H, Katsumata N, Ando M, Watanabe T. (2010). Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol 33:32–35.
   PubMedGoogle Scholar
• Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Bátkai S, Gao B, Haskó G, Pacher P. (2010). Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 48:457–467.
   PubMed Web of Science ®Google Scholar
• Nakayama T, Sato W, Yoshimura A, Zhang L, Kosugi T, Campbell-Thompson M, Kojima H, Croker BP, Nakagawa T. (2010). Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney. Am J Pathol 176:2198–2208.
   PubMed Web of Science ®Google Scholar
• Nangaku M. (2004). Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol 98:e8–12.
   Google Scholar
• Nazneen A, Razzaque MS, Liu D, Taguchi T. (2002). Possible role of Ets-1 and MMP-1 in matrix remodeling in experimental cisplatin nephropathy. Med Electron Microsc 35:242–247.
   PubMedGoogle Scholar
• Nezhat F, Wadler S, Muggia F, Mandeli J, Goldberg G, Rahaman J, Runowicz C, Murgo AJ, Gardner GJ. (2004). Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study. Gynecol Oncol 93:144–148.
   PubMed Web of Science ®Google Scholar
• Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T. (2000). Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 46:459–466.
   PubMedGoogle Scholar
• Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA. (1989). Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp Mol Pathol 51:123–140.
   PubMedGoogle Scholar
• Noris M, Remuzzi G. (2008). Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin Exp Immunol 151:199–209.
   PubMedGoogle Scholar
• Owens DM, Keyse SM. (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26:3203–3213.
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z. (2008). Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994–1007.
   PubMed Web of Science ®Google Scholar
• Pabla N, Murphy RF, Liu K, Dong Z. (2009). The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296:F505–F511.
   PubMed Web of Science ®Google Scholar
• Park TK, Kim SN, Kim SW, Kim GE, Suh CO. (2000). Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. J Korean Med Sci 15:436–441.
   PubMedGoogle Scholar
• Peyrou M, Hanna PE, Cribb AE. (2007). Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci 99:346–353.
   PubMed Web of Science ®Google Scholar
• Ramesh G, Reeves WB. (2002). TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835–842.
   PubMed Web of Science ®Google Scholar
• Ramesh G, Reeves WB. (2003). TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610–F618.
   PubMed Web of Science ®Google Scholar
• Ramesh G, Reeves WB. (2004). Inflammatory cytokines in acute renal failure. Kidney Int Suppl: S56–S61.
   Google Scholar
• Ramesh G, Reeves WB. (2005). p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol 289:F166–F174.
   PubMed Web of Science ®Google Scholar
• Ramesh G, Kimball SR, Jefferson LS, Reeves WB. (2007). Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol 292:F812–F819.
   Google Scholar
• Razzaque MS, Koji T, Kumatori A, Taguchi T. (1999). Cisplatin-induced apoptosis in human proximal tubular epithelial cells is associated with the activation of the Fas/Fas ligand system. Histochem Cell Biol 111:359–365.
   PubMed Web of Science ®Google Scholar
• Razzaque MS, Harada T, Taguchi T. (1996). Significance of increased accumulation of type VI collagen and transforming growth factor beta 1 in tubulointerstitial damage in hypertensive nephrosclerosis: an immunohistochemical study. J Int Med Res 24:199–208.
   PubMedGoogle Scholar
• Retz M, Lehmann J, Trocha C, Loch T, Seppelt U, Fischer C, Pinkenburg FA, Timm KJ, Wellek S, Stöckle M. (2000). Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma. Cancer 89:1089–1094.
   PubMedGoogle Scholar
• Rinaldi M, Crinò L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, Selvaggi G, Della Giulia M, Darwish S, Porrozzi S, Novello S, Cipri A, Bartolucci R, Calandri C, Tonato M. (2000). A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 11:1295–1300.
   PubMedGoogle Scholar
• Rodriguez-Barbero A, L’Azou B, Cambar J, López-Novoa JM. (2000). Potential use of isolated glomeruli and cultured mesangial cells as in vitro models to assess nephrotoxicity. Cell Biol Toxicol 16:145–153.
   PubMed Web of Science ®Google Scholar
• Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G. (2002). Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539–1549.
   PubMed Web of Science ®Google Scholar
• Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X. (2005). Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs 16:1009–1016.
   PubMed Web of Science ®Google Scholar
• Saad SY, Arafah MM, Najjar TA. (2007). Effects of mycophenolate mofetil on cisplatin-induced renal dysfunction in rats. Cancer Chemother Pharmacol 59:455–460.
   PubMed Web of Science ®Google Scholar
• Saad AA, Youssef MI, El-Shennawy LK. (2009). Cisplatin induced damage in kidney genomic DNA and nephrotoxicity in male rats: the protective effect of grape seed proanthocyanidin extract. Food Chem Toxicol 47:1499–1506.
   PubMed Web of Science ®Google Scholar
• Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. (1986). Cisplatin nephrotoxicity. Am J Kidney Dis 8:356–367.
   PubMed Web of Science ®Google Scholar
• Saleh S, El-Demerdash E. (2005). Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 97:91–97.
   PubMed Web of Science ®Google Scholar
• Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC. (2008). Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 61:145–155.
   PubMed Web of Science ®Google Scholar
• Sárosi V, Lénárt T. (2003). Gemcitabine-cisplatin combination in the first line treatment of non-small cell lung cancer. Our experience and analysis of safety. Magy Onkol 47:189–193.
   PubMedGoogle Scholar
• Sastry J, Kellie SJ. (2005). Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr Hematol Oncol 22:441–445.
   PubMed Web of Science ®Google Scholar
• Schäfer A, Bauersachs J. (2008). Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 6:52–60.
   PubMed Web of Science ®Google Scholar
• Schnermann J, Levine DZ. (2003). Paracrine factors in tubuloglomerular feedback: adenosine, ATP, and nitric oxide. Annu Rev Physiol 65:501–529.
   PubMed Web of Science ®Google Scholar
• Schrier RW, Chen YC, Cadnapaphornchai MA. (2004). From finch to fish to man: role of aquaporins in body fluid and brain water regulation. Neuroscience 129:897–904.
   PubMed Web of Science ®Google Scholar
• Sculier JP, Lafitte JJ, Efremidis A, Florin MC, Lecomte J, Berchier MC, Richez M, Berghmans T, Scherpereel A, Meert AP, Koumakis G, Leclercq N, Paesmans M, Van Houtte P; European Lung Cancer Working Party (ELCWP). (2008). A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer. Ann Oncol 19:1691–1697.
   PubMedGoogle Scholar
• Sekine I, Sumi M, Ito Y, Kato T, Fujisaka Y, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. (2007). Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Jpn J Clin Oncol 37:175–180.
   PubMedGoogle Scholar
• Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. (2005). p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 280:31230–31239.
   PubMed Web of Science ®Google Scholar
• Shamseddine AI, Otrock ZK, Khalifeh MJ, Yassine HR, Charafeddine M, Abdel-Khalek Z, Chehal A, Bitar N, Jalloul R, Dheiny M, Dandashi A, Wehbeh M, El-Saghir NS. (2006). A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer. Oncology 70:330–338.
   PubMedGoogle Scholar
• Shord SS, Thompson DM, Krempl GA, Hanigan MH. (2006). Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs 17:207–215.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279.
   PubMed Web of Science ®Google Scholar
• Skálová S. (2005). The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment. Acta Medica (Hradec Kralove) 48:75–80.
   PubMedGoogle Scholar
• Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. (2009). Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213–3219.
   PubMed Web of Science ®Google Scholar
• Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS, Lee S, Kim W, Davaatseren M, Hwang JT, Kim HJ, Kim MS, Kwon DY, Park SK. (2008). Genistein protects the kidney from cisplatin-induced injury. Kidney Int 74:1538–1547.
   PubMed Web of Science ®Google Scholar
• Taguchi T, Nazneen A, Abid MR, Razzaque MS. (2005). Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 148:107–121.
   PubMed Web of Science ®Google Scholar
• Tamada S, Asai T, Kuwabara N, Iwai T, Uchida J, Teramoto K, Kaneda N, Yukimura T, Komiya T, Nakatani T, Miura K. (2006). Molecular mechanisms and therapeutic strategies of chronic renal injury: the role of nuclear factor kappaB activation in the development of renal fibrosis. J Pharmacol Sci 100:17–21.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kojima I, Ohse T, Inagi R, Miyata T, Ingelfinger JR, Fujita T, Nangaku M. (2005). Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. Am J Physiol Renal Physiol 289:F1123–F1133.
   Web of Science ®Google Scholar
• Thadhani R, Pascual M, Bonventre JV. (1996). Acute renal failure. N Engl J Med 334:1448–1460.
   PubMed Web of Science ®Google Scholar
• Tiseo, M., Boni, L., and Ardizzoni, A.(2006). Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference? J Clin Oncol 23:6276–6277; author reply 6277–6278.
   Google Scholar
• Togna GI, Togna AR, Franconi M, Caprino L. (2000). Cisplatin triggers platelet activation. Thromb Res 99:503–509.
   PubMed Web of Science ®Google Scholar
• Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. (2003). Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1–10.
   PubMed Web of Science ®Google Scholar
• Tsang RY, Al-Fayea T, Au HJ. (2009). Cisplatin overdose: toxicities and management. Drug Saf 32:1109–1122.
   PubMed Web of Science ®Google Scholar
• Tsuji T, Kato A, Yasuda H, Miyaji T, Luo J, Sakao Y, Ito H, Fujigaki Y, Hishida A. (2009). The dimethylthiourea-induced attenuation of cisplatin nephrotoxicity is associated with the augmented induction of heat shock proteins. Toxicol Appl Pharmacol 234:202–208.
   PubMedGoogle Scholar
• Tsuruya K, Tokumoto M, Ninomiya T, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Hirakata H, Iida M. (2003). Antioxidant ameliorates cisplatin-induced renal tubular cell death through inhibition of death receptor-mediated pathways. Am J Physiol Renal Physiol 285:F208–F218.
   PubMed Web of Science ®Google Scholar
• Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, Maruyama T. (2005). Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 79:451–460.
   PubMedGoogle Scholar
• Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R, Thomas H, Davis J, Eggleton SP, Kaye SB. (1999). Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 17:2069–2080.
   PubMed Web of Science ®Google Scholar
• Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. (2008). Cardiovascular risk in long-term survivors of testicular cancer. Cancer 112:1949–1953.
   PubMed Web of Science ®Google Scholar
• Vickers AE, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P. (2004). Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol 32:577–590.
   PubMed Web of Science ®Google Scholar
• Victor VM, Rocha M, Solá E, Bañuls C, Garcia-Malpartida K, Hernández-Mijares A. (2009). Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 15:2988–3002.
   PubMed Web of Science ®Google Scholar
• Wainford RD, Weaver RJ, Stewart KN, Brown P, Hawksworth GM. (2008). Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology 249:184–193.
   PubMedGoogle Scholar
• Wang D, Lippard SJ. (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307–320.
   PubMed Web of Science ®Google Scholar
• Wei Q, Dong G, Yang T, Megyesi J, Price PM, Dong Z. (2007a). Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol 293:F1282–F1291.
   PubMed Web of Science ®Google Scholar
• Wei Q, Dong G, Franklin J, Dong Z. (2007b). The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72:53–62.
   PubMed Web of Science ®Google Scholar
• Winston JA, Safirstein R. (1985). Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat. Am J Physiol 249:F490–F496.
   PubMed Web of Science ®Google Scholar
• Yamate J, Sato K, Ide M, Nakanishi M, Kuwamura M, Sakuma S, Nakatsuji S. (2002). Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet Pathol 39:322–333.
   PubMedGoogle Scholar
• Yamate J, Machida Y, Ide M, Kuwamura M, Kotani T, Sawamoto O, LaMarre J. (2005). Cisplatin-induced renal interstitial fibrosis in neonatal rats, developing as solitary nephron unit lesions. Toxicol Pathol 33:207–217.
   PubMedGoogle Scholar
• Yang T, Vesey DA, Johnson DW, Wei MQ, Gobe GC. (2007). Apoptosis of tubulointerstitial chronic inflammatory cells in progressive renal fibrosis after cancer therapies. Transl Res 150:40–50.
   PubMedGoogle Scholar
• Yao X, Panichpisal K, Kurtzman N, Nugent K. (2007). Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124.
   PubMed Web of Science ®Google Scholar
• Yatsu T, Aoki M, Inagaki O. (2003). Preventive effect of zelandopam, a dopamine D1 receptor agonist, on cisplatin-induced acute renal failure in rats. Eur J Pharmacol 461:191–195.
   PubMedGoogle Scholar
• Yokoo K, Murakami R, Matsuzaki T, Yoshitome K, Hamada A, Saito H. (2009). Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 13:578–584.
   PubMed Web of Science ®Google Scholar
• Yoshiki N, Kubota T, Aso T. (2000). Expression and localization of inducible nitric oxide synthase in human non-pregnant and early pregnant endometrium. Mol Hum Reprod 6:283–287.
   PubMed Web of Science ®Google Scholar
• Zhang L, Hanigan MH. (2003). Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin. J Pharmacol Exp Ther 306:988–994.
   PubMed Web of Science ®Google Scholar
• Zhang B, Ramesh G, Norbury CC, Reeves WB. (2007). Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 72:37–44.
   PubMed Web of Science ®Google Scholar
• Zhang B, Ramesh G, Uematsu S, Akira S, Reeves WB. (2008). TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J Am Soc Nephrol 19:923–932.
   PubMed Web of Science ®Google Scholar
• Zhou H, Kato A, Yasuda H, Miyaji T, Fujigaki Y, Yamamoto T, Yonemura K, Hishida A. (2004). The induction of cell cycle regulatory and DNA repair proteins in cisplatin-induced acute renal failure. Toxicol Appl Pharmacol 200:111–120.
   PubMed Web of Science ®Google Scholar